Macquarie Reports Imperial Oil (IMO) Upgrade from “Underperform”; Bvf Has Lowered By $2.17 Million Its Chemocentryx (CCXI) Holding

Imperial Oil Limited (NYSEAMERICAN:IMO) Logo

Imperial Oil (IMO)‘s rating was boosted by expert analysts at Macquarie from a “Underperform” rating to a “Neutral” rating in a analysts note issued to clients on 28 November.

Bvf Inc decreased Chemocentryx Inc (CCXI) stake by 2.32% reported in 2018Q2 SEC filing. Bvf Inc sold 166,970 shares as Chemocentryx Inc (CCXI)’s stock declined 9.17%. The Bvf Inc holds 7.03 million shares with $92.64 million value, down from 7.20 million last quarter. Chemocentryx Inc now has $500.71M valuation. The stock decreased 0.90% or $0.09 during the last trading session, reaching $9.91. About 39,893 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since November 28, 2017 and is uptrending. It has outperformed by 35.68% the S&P500. Some Historical CCXI News: 09/05/2018 – ChemoCentryx 1Q Loss/Shr 19c; 11/04/2018 – ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting; 09/03/2018 – ChemoCentryx 4Q Rev $56.3M; 10/05/2018 – Invus Public Equities Advisors Exits Position in ChemoCentryx; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/05/2018 – CHEMOCENTRYX INC – QTRLY DILUTED NET LOSS PER COMMON SHARE $0.19

More notable recent Imperial Oil Limited (NYSEAMERICAN:IMO) news were published by: which released: “LiqTech International, Inc. Announces Third Quarter 2018 Financial Results – Stockhouse” on November 14, 2018, also with their article: “Goldman Sachs picks its favorites among major oil companies, refiners – MarketWatch” published on April 07, 2017, published: “LiqTech International, Inc. Announces Second Quarter 2018 Financial Results – PR Newswire” on August 14, 2018. More interesting news about Imperial Oil Limited (NYSEAMERICAN:IMO) were released by: and their article: “Lithium investors need look no further than Galaxy Resources – InvestorIntel” published on July 23, 2018 as well as‘s news article titled: “LiqTech Signs Framework Agreement With Marine Scrubber Manufacturer – PR Newswire” with publication date: March 21, 2018.

The stock increased 1.30% or $0.39 during the last trading session, reaching $30.38. About 99,225 shares traded. Imperial Oil Limited (IMO) has declined 5.20% since November 28, 2017 and is downtrending. It has underperformed by 20.82% the S&P500.

Imperial Oil Limited explores for, produces, and sells natural gas and crude oil in Canada. The company has market cap of $24.19 billion. The firm operates through three divisions: Upstream, Downstream, and Chemical. It has a 25.07 P/E ratio. The Upstream segment explores for and produces crude oil, natural gas, synthetic oil, and bitumen.

Investors sentiment increased to 1.59 in Q2 2018. Its up 0.59, from 1 in 2018Q1. It increased, as 11 investors sold CCXI shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported. Bb&T Limited Liability Co stated it has 98,500 shares or 0.01% of all its holdings. Amer Group Inc has 14,278 shares for 0% of their portfolio. Meeder Asset Management Inc stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Ameriprise Financial owns 70,321 shares. Tiaa Cref Invest Ltd Liability Corporation has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Renaissance Limited has invested 0.01% in ChemoCentryx, Inc. (NASDAQ:CCXI). Piermont Capital Management reported 19,360 shares. Prudential has invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Franklin Resources holds 0.01% or 1.52 million shares in its portfolio. Dimensional Fund Ltd Partnership owns 321,286 shares or 0% of their US portfolio. Aqr Capital Ltd Liability reported 22,364 shares stake. Bridgeway invested 0% of its portfolio in ChemoCentryx, Inc. (NASDAQ:CCXI). Paloma Mgmt Com reported 12,100 shares. Parametric Port Associate Limited Liability Corp reported 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Smith Asset Management Gru LP reported 26,447 shares.

Among 4 analysts covering ChemoCentryx (NASDAQ:CCXI), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. ChemoCentryx had 4 analyst reports since June 28, 2018 according to SRatingsIntel. As per Tuesday, August 14, the company rating was downgraded by JP Morgan. On Monday, November 12 the stock rating was maintained by Canaccord Genuity with “Buy”.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *